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The hypothalamic orexin neuropeptide acutely pro-
motes appetite, yet orexin deficiency in humans
and mice is associated with obesity. Prolonged ef-
fects of increased orexin signaling upon energy ho-
meostasis have not been fully characterized. Here,
we examine the metabolic effects of orexin gain of
function utilizing genetic and pharmacologic tech-
niques in mice. Transgenic orexin overexpression
confers resistance to high-fat diet-induced obesity
and insulin insensitivity by promoting energy expen-
diture and reducing consumption. Genetic studies
indicate that orexin receptor-2 (OX2R), rather than
OX1R signaling, predominantly mediates this pheno-
type. Likewise, prolonged central administration of
an OX2R-selective peptide agonist inhibits diet-
induced obesity. While orexin overexpression en-
hances the anorectic-catabolic effects of central
leptin administration, obese leptin-deficient mice
are completely resistant to the metabolic effects of
orexin overexpression or OX2R agonist infusion.
We conclude that enhanced orexin-OX2R signaling
confers resistance to diet-induced features of the
metabolic syndrome through negative energy ho-
meostasis and improved leptin sensitivity.
INTRODUCTION
Animals employ genetically and physiologically determined ho-
meostatic mechanisms to prevent excess weight gain; however,
this regulation may be circumvented by environmental and he-
donic factors. The ready availability of palatable, calorically
dense food and the reduced need for physical activity in modern
life have resulted in a pandemic of obesity. Rodent models have
elucidated the mechanisms and modulators of body weight ho-
meostasis such as the fat tissue-derived satiety hormone leptin64 Cell Metabolism 9, 64–76, January 7, 2009 ª2009 Elsevier Inc.(Enriori et al., 2007; Myers et al., 2008). Leptin centrally regulates
body weight by suppressing food intake and permitting energy
expenditure. While absence of leptin in rodents causes hyper-
phagia, obesity, and diabetes, most human obesity is associated
with hyperleptinemic leptin resistance.
Orexins (also known as hypocretins) are lateral hypothalamic
neuropeptides that are upregulated with fasting and can acutely
promote appetite when administered into the central nervous
system (Sakurai et al., 1998). The two receptors for orexin,
type 1 (OX1R) and type 2 (OX2R), show differential affinity for
the products of the prepro-orexin gene, orexin-A and orexin-B
(Sakurai et al., 1998). OX1R andOX2R exhibit distinct expression
patterns, indicating distinct roles in behavior and metabolism.
The arcuate nucleus of hypothalamus (ARH) is a point of conver-
gence for both orexin and leptin signaling, which modulate the
activities of neuropeptide regulators of food intake and metabo-
lism such as neuropeptide Y (NPY), agouti-related peptide
(AGRP), and pro-opiomelanocortin (POMC). Pathologic leptin re-
sistance may be mediated by changes in second messengers,
including the long form of leptin receptor (LEPR), downstream
signal transducer and activator of transcription-3 (STAT3), or
the feedback suppressor of cytokine signal-3 (SOCS3) (Horvath,
2005; Myers et al., 2008).
Central administration of orexin neuropeptides to rodents
acutely promotes appetite, and prepro-orexin deficiency or
postgestational ablation of orexin neurons in mice causes mod-
est reductions in food intake. However, orexin-deficient mice
also exhibit narcolepsy, inactivity, and obesity, indicating that
orexin may exert an overall catabolic influence upon energy bal-
ance (Hara et al., 2001, 2005; Willie et al., 2001). Narcoleptic hu-
man individuals (the majority of which are orexin deficient) have
also been reported to have greater body mass index and higher
incidence of metabolic syndrome (Nishino, 2007). This effect of
orexin upon energy balance may be primary, since orexin-defi-
cient narcoleptic patients showed higher body mass index
than otherwise clinically indistinguishable narcoleptics with nor-
mal orexin levels (Nishino et al., 2001).
As the conclusion that orexin promotes negative energy bal-
ance derives indirectly from loss-of-function studies, we utilized
genetic and pharmacological methods to directly examine
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balance. First, using CAG/orexin transgenic mice (Mieda et al.,
2004) that overproduce orexin neuropeptides from an ectopi-
cally expressed transgene, we examined the effects of constitu-
tively increased orexin signaling upon diet-induced obesity by
measuring adiposity, locomotor activity, and other metabolic pa-
rameters. To differentiate the role of each receptor pathway, we
also examined the effects of the CAG/orexin transgene upon
OX1R knockout mice (OX1R/, Kisanuki et al., 2001) and
OX2R knockoutmice (OX2R/,Willie et al., 2003). Results of ge-
netic studies were then verified and extended pharmacologically
using a selective agonist for OX2R. Finally, we sought to deter-
mine the effect of the CAG/orexin transgene upon leptin-defi-
cient ob/ob mice, examined the sensitivity of CAG/orexin mice
to central leptin administration, and investigated the effects of
selective OX2R agonism upon ob/ob mice.
RESULTS
Expression of Orexin Peptide in CAG/Orexin Mouse
Previous results with CAG/orexin transgenic mice revealed mul-
tifold increases in both orexin-A and orexin-B peptides in whole
brain extracts (Mieda et al., 2004). Immunohistochemical locali-
zation of orexin-A in the brain of CAG/orexinmice demonstrates
ectopic peptide production in medial, basal, lateral, and supra-
chiasmatic hypothalamic nuclei, nucleus accumbens, globus
pallidus, hippocampal formation, ventral tegmental area, and
locus coerulus (Figures S1 and S2, Table S1). All of these loca-
tions have previously been implicated as participants in net-
works controlling various homeostatic, circadian, learned, and/
or hedonistic aspects of food intake, taste preference, or energy
homeostasis (Saper et al., 2002). Previous results demonstrated
that CAG/orexin transgene insertion was sufficient to rescue the
narcolepsy/cataplexy phenotype of mice lacking endogenous
orexinergic neurons (Mieda et al., 2004). Thus, the CAG/orexin
transgene produces functional peptides that can activate orexin
receptors.
The physiological relevance of peripheral actions of orexins, if
any, remains controversial (Heinonen et al., 2008). In spite of the
use of a general promoter for orexin overexpression, we found
that CAG/orexin mice exhibited ectopic orexin-A immunoreac-
tivity in a limited set of peripheral tissues, including thyroid gland,
adrenal cortex, and some pancreatic islets. No evidence of ec-
topic expression was encountered in other metabolic tissues
such as brown and white adipose, liver, or skeletal muscle
(Figure S3, Tables S2 and S3).
CAG/OrexinMice are Resistant to Diet-Induced Obesity
To examine the effect of increased orexin on body weight, CAG/
orexin transgenic mice and wild-type littermate mice were fed ei-
ther a low- or a high-fat diet. In both male and female mice, the
body weights of wild-type mice were significantly higher when
fed a high-fat diet compared to a low-fat diet. However, mice
overexpressing orexin did not show a significant difference in
body weight growth between a low-fat diet and a high-fat diet
(Figures 1A and 1B). Thus, wild-type mice are susceptible to
diet-induced obesity, whereas CAG/orexin mice are quite
resistant.To determine which receptor pathway mediates the antiobe-
sity effect of orexin overexpression, we crossed CAG/orexin
transgenic mice to OX1R/ and OX2R/ lines. We compared
the effects of isolated orexin-OX2R signaling (in OX1R/ mice
and OX1R/; CAG/orexin mice) versus isolated orexin-OX1R
signaling (in OX2R/ mice and OX2R/; CAG/orexin mice)
upon growth curves. Figures 1C and 1D show that increased
OX2R activation is sufficient tomediate the preponderance of re-
sistance to diet-induced obesity. On the other hand, in both
sexes, increased OX1R activation alone does not significantly
protect from development of obesity (Figures 1E and 1F). Unlike
differences in body weight, there were no significant differences
in linear growth among the various genotypic groups (data not
shown). Thus, OX2R signaling selectively mediates the antiobe-
sity effect of orexin overexpression in mice challenged with
a high-fat diet.
CAG/orexin-transgenic male mice were also resistant to ag-
ing-related adiposity, while wild-type male mice fed a low-fat
diet showed continuous weight gain during aging (Figure 1A).
In spite of similar growth curves before 18 weeks of age, the
growth curve between 19 and 30 weeks of age of wild-type
mice fed a low-fat diet was significantly larger than that of
CAG/orexin-transgenic mice (p = 0.0016). Likewise, OX1R/
male mice fed a low-fat diet showed larger body weight growth
between 17 and 30 weeks of age than OX1R/; CAG/orexin
mice despite no significant difference in the growth curves be-
fore 16 weeks of age (p = 0.036). OX2R/ male mice fed
a low-fat diet showed larger body weight than OX2R/; CAG/
orexin mice through the whole observation period (p = 0.005);
however, the fat mass and serum leptin ofOX2R/;CAG/orexin
malemice were similar to those ofOX2R/malemice (Figure 2).
CAG/Orexin Transgene Reduces Fat Mass and Leptin
Consistent with body weight data, at 28 weeks of age, CAG/
orexin male mice showed a significant reduction of fat mass on
a low-fat diet as compared with wild-type male mice (Figure 2A).
The fat mass of CAG/orexin male mice and OX1R/; CAG/
orexin mice fed a high-fat diet was significantly less than those
of wild-type mice and OX1R/ mice, respectively, for both
sexes (Figures 2A and 2B). There was no significant difference
in fat mass between OX2R/ mice and OX2R/; CAG/orexin
mice on both a low-fat and a high-fat diet for either sex.
OX2R/ male mice exhibited a significant tendency toward in-
creased fatmass under high-fat conditions, andOX2R/ female
mice exhibited a mild but significant tendency toward increased
fat mass under even low-fat conditions compared to wild-type
mice, which is consistent with previously described adiposity
of narcoleptic mice (Hara et al., 2001) and a physiological role
of OX2R signaling in suppressing adiposity.
Next, we measured serum leptin, which typically correlates
with fat mass. Concordance between fat mass and leptin levels
was confirmed in each genotype. Specifically, the leptin levels of
CAG/orexinmice and of OX1R/; CAG/orexinmice were signif-
icantly lower than those of wild-type mice and of OX1R/ mice
fed a high-fat diet, respectively, whereas there was no significant
difference in serum leptin levels between OX2R/; CAG/orexin
mice and OX2R/ mice on both low-fat and high-fat diets for
both sexes (Figures 2C and 2D). Compared to differences ob-
served in fat mass, the CAG/orexin transgene was associatedCell Metabolism 9, 64–76, January 7, 2009 ª2009 Elsevier Inc. 65
with small but significant reductions in lean mass of male mice
having functional orexin receptors and those deficient in OX1R
under high-fat conditions (Figure 2E). The CAG/orexin transgene
was similarly associated with a significant mild reduction in lean
mass of female mice having functional receptors under high-fat
conditions, but a significant mild reduction of lean mass by the
transgene under OX2R-deficient low-fat conditions was also
observed (Figure 2F).
Increased Energy Expenditure of CAG/Orexin Mice
To explore the underlying cause of differential resistance to diet-
induced obesity in mice overexpressing orexin, we housed mice
from each genotypic group in metabolic cages in order to mea-
sure oxygen consumption, carbon dioxide production, and loco-
motor activity. The effective mass-corrected energy expendi-
tures of CAG/orexin male mice and OX1R/; CAG/orexin mice
on a high-fat diet were consistently elevated over those of
Figure 1. Growth Curves of Genetically
Modified Mice Fed a Low- or High-Fat Diet
(A–F) Body weights of micemeasured weekly from
the age of 3 weeks to 30 weeks. A high-fat diet
started at the age of 8 weeks (dotted line). The
numbers of mice are 10–14 mice per group. * indi-
cates significant difference between different diet
condition for each genotypic group according to
post hoc analysis at each time point. Significant
differences in (F) for OX2R/ mice and OX2R/;
CAG/orexin are indicated by one asterisk. Data are
expressed as means ± SEM. Body weight curves
of wild-type male (A) and female (B) mice on
a high-fat diet were significantly higher than those
of wild-type mice on a low-fat diet (p < 0.0005,
both sexes). CAG/orexinmice did not differ signif-
icantly under low-fat and high-fat dietary condi-
tions (p = 0.51 male; p = 0.13 female). Body weight
curves of OX1R/ male (C) and female (D) mice
on a high-fat diet were significantly higher than
those of OX1R/ mice on a low-fat diet (p <
0.0001 male; p < 0.01 female). OX1R/; CAG/
orexin male mice did not differ significantly be-
tween low-fat and high-fat dietary conditions (p =
0.21). The body weights of OX1R/; CAG/orexin
female mice on a high-fat diet were significantly
less than those of OX1R/ mice on a high-fat
diet (p < 0.01), in spite of no bodyweight difference
between OX1R/; CAG/orexin female mice and
OX1R/ female mice on a low-fat diet (p = 0.50).
The body weight growths ofOX2R/male (E) and
female (F) mice on a high-fat diet were significantly
higher than those of OX2R/ mice on a low-fat
diet (p < 0.0001 male; p < 0.005 female). Likewise,
OX2R/;CAG/orexinmale (E) and female (F) mice
showed significant weight gain on a high-fat diet
compared to those on a low-fat diet (p < 0.0005
male; p < 0.001 female).
wild-type mice and OX1R/ mice, re-
spectively (Figures 3A, 3C, and 3G), while
the energy expenditures of OX2R/;
CAG/orexin mice resembled those of
OX2R/ mice (Figures 3E and 3G). In
contrast, we observed no consistent differences in respiratory
quotient (RQ; an indirect indicator of lipid versus carbohydrate
utilization) among different genotypic groups on a high-fat diet
(Figures 3B, 3D, 3F, and 3H). TheCAG/orexin transgene induced
no differences in energy expenditure or RQ among any geno-
typic groups on a low-fat diet, regardless of the presence or ab-
sence of orexin receptors (Figure S4). Low-fat-fedOX1R/mice
showed reduced energy expenditure compared to wild-type
controls (Figure S4G). Importantly, CAG/orexin transgenic mice
did not exhibit hyperactivity, regardless of diet or receptor status
(Figure S5), although OX2R/ mice fed a low-fat diet showed
some reduced locomotion compared to wild-type mice (Fig-
ure S5G), which is consistent with previous data from narcoleptic
mice (Hara et al., 2001, 2005). Basal core body temperature in
CAG/orexin mice on a high-fat diet tended to be higher than in
wild-type controls, but this difference did not reach significance
(wild-type low-fat diet: 36.6C ± 0.1C; CAG/orexin low-fat
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diet: 36.7C ± 0.1C; wild-type high-fat diet: 36.8C ± 0.1C;
CAG/orexin high-fat diet: 37.0C ± 0.1C; n = 5–6).
Both total high-fat diet intake for 14 days (Figure 3I) and body
weight-adjusted daily food intake (data not shown) were signifi-
cantly reduced in CAG/orexin mice compared to wild-type con-
trols. Critically, this did not result from abnormal taste prefer-
ences: compared to wild-type mice, CAG/orexin and wild-type
mice similarly exhibited greater preferences for high-fat over
low-fat chow and for 10% sucrose over 1% sucrose solutions
(Figure S6).
Glucose Metabolism of CAG/Orexin Mice
To examine the effect of orexin overexpression on glucose me-
tabolism, we first measured blood glucose and serum insulin
of fed mice at 30 weeks of age. When maintained on a low-fat
diet, we observed no significant difference in fed glucose level
Figure 2. Fat Mass, Serum Leptin Levels,
and Lean Mass of Orexin Signaling-
Modified Mice
(A and B) The fat masses of male (A) and female (B)
mice at 28 weeks of age on different diets.
(C and D) The serum leptin of male (C) and female
(D) mice at 30 weeks of age on different diets.
(E and F) The lean masses of male (E) and female
(F) mice at 28 weeks of age on different diets. * in-
dicates significant (p < 0.05) increase compared to
wild-type mice under the same food condition.
The numbers of mice are 8–14 mice per group.
Data are expressed as means ± SEM.
among genotypes (Figure 4A). On
a high-fat diet, however, wild-type mice
exhibited hyperglycemia that is attenu-
ated in CAG/orexin, OX1R/, and
OX1R/; CAG/orexin mice, but not
OX2R/ or OX2R/; CAG/orexin mice.
Thus, the protective effect depends
upon functional OX2R, but can be medi-
ated by endogenous orexin levels even
without orexin overexpression. Notably,
these data also show that OX1R defi-
ciency alone can prevent high-fat diet-
induced hyperglycemia (see below).
Increased serum insulin levels with
obesity or aging indicatemounting insulin
resistance and sensitively predict deteri-
orating glucose control in human meta-
bolic syndrome. When compared to
wild-type mice, the CAG/orexin trans-
gene reduced serum insulin levels on a
low-fat diet and conferred protection
from hyperinsulinemia on high-fat diet
(Figure 4B). Notably, a similar protective
effect occurred in OX1R/ mice (Fig-
ure 4B), despite relative obesity under
these conditions (Figures 1C, 1D, 2C,
and 2D), suggesting that endogenous
orexin-OX1R signaling can play a specific
permissive role in development of hyperinsulinemia. However,
the CAG/orexin transgene conferred protection from hyperinsu-
linemia upon all three genetic backgrounds on a high-fat diet,
suggesting that both OX1R andOX2Rmediate protective effects
of orexin overexpression on insulin sensitivity.
We next examined the effects of orexin overexpression upon
fasting glucose and glucose tolerance after glucose administra-
tion in mice. On a low-fat diet, orexin overexpression did not sig-
nificantly affect glucose homeostasis (p = 0.47, Figure S7). On
a high-fat diet, however, CAG/orexinmice exhibited significantly
reduced basal fasting glucose levels as well as improved glu-
cose tolerance at all time points tested, relative to wild-type con-
trols (Figure 4C). Despite absence of basal differences in fasting
serum glucose between OX1R/ and OX1R/; CAG/orexin
mice, the CAG/orexin transgene conferred mild but significant
improvements in glucose tolerance onto the OX1R/
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background at later time points (Figure 4D). Improved glucose
tolerance in the setting of reduced insulin levels indicates that
the transgene confers improved insulin sensitivity. By contrast,
we observed no significant differences in fasting glucose or glu-
cose tolerance between OX2R/ mice and OX2R/; CAG/
orexinmice (Figure 4E). Thus, while OX1Rmay also influence cir-
culating insulin levels, orexin overexpression improves insulin
sensitivity by a predominantly OX2R-dependent mechanism.
Effects of CAG/Orexin Transgene on Peripheral Tissues
Ectopic orexin production in thyroid tissue raises the possibility
that abnormal activity of the thyroid axis contributes to leanness
Figure 3. The Metabolic Parameters of Orexin Signaling-Modified Mice on a High-Fat Diet
(A and B) The energy expenditure with effective mass correction (A) and respiratory quotient (B) sampled every 40 min over 24 hr of CAG/orexin mice and wild-
type mice at 16–20 weeks of age.
(C and D) The energy expenditure with effective mass correction (C) and respiratory quotient (D) over 24 hr of OX1R/; CAG/orexin mice and OX1R/ mice.
(E and F) The energy expenditure with effective mass correction (E) and respiratory quotient (F) over 24 hr of OX2R/; CAG/orexin mice and OX2R/ mice.
(G and H) The averaged energy expenditure with effective mass correction (G) and respiratory quotient (H).
(I) Averaged daily high-fat diet intake of CAG/orexin mice and wild-type mice for 14 days. The numbers of mice are 6–9 mice per group. Data are expressed as
means ± SEM.
Figure 4. Glucose Metabolism of Orexin Signaling-Modified Mice on Different Fat Diets
(A) Blood glucose levels of orexin-related gene mutant mice on different fat diets.
(B) Serum insulin levels of orexin-related gene mutant mice on different fat diets.
(C) Glucose tolerance test showed that the blood glucose levels of CAG/orexinmice were significantly lower than those of wild-type littermate mice on a high-fat
diet after the administration of glucose.
(D) Glucose tolerance test showed that the blood glucose levels ofOX1R/; CAG/orexinmice were significantly lower than those ofOX1R/mice on a high-fat
diet after the administration of glucose. Data are expressed as means ± SEM.
(E) Glucose tolerance test showed that there is no significant difference in the blood glucose levels between OX2R/; CAG/orexin mice and OX2R/ mice on
a high-fat diet after the administration of glucose (p = 0.33). The numbers of mice are 8–14 mice (A and B) and 6–10 mice (C–E) per group. Data are expressed as
means ± SEM (*p < 0.05).
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Figure 5. Effect of OX2R Selective Agonist on Diet-Induced Obesity
(A) The daily body weight changes of chronically ICV-injected mice. ICV and high-fat diet begin at day 0. The body weight growths of the OX2R selective agonist-
injected mice (0.5 nmol/day) are significantly lower than those of vehicle-injected mice on a high-fat diet (p < 0.0005), whereas there is no significant difference in
the body weight growth between them on a low-fat diet (p = 0.45).
(B) The fat mass change after the infusion of OX2R-selective agonist or vehicle for 14 days under a low- or high-fat diet.
(C) The oxygen consumption with effective mass correction of OX2R agonist-infused mice on a high-fat diet was higher than vehicle-infused mice (p < 0.0005,
repeated ANOVA). Data were sampled every 30 min.
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in CAG/orexin mice. We measured serum thyroid stimulating
hormone (TSH), triiodothyronine (T3), and thyroxine (T4) on
low- and high-fat diets. High-fat diet increased serum T3 and
T4 levels of CAG/orexin mice to an extent similar to wild-type
mice despite significant differences in adiposity between the
groups (Figure S8). Serum TSH levels of CAG/orexin mice on
a high-fat diet were significantly elevated over those on a low-
fat diet, while a high-fat diet did not significantly affect serum
TSH levels of wild-type mice. Importantly, the levels of serum
TSH, T3, and T4 of CAG/orexin mice were similar to those of
wild-type mice when maintained on a low-fat diet.
To determine whether increased energy expenditure of CAG/
orexinmicewas associatedwith increasedmitochondrial uncou-
pling proteins, we examined mRNA levels of major uncoupling
proteins in brown fat and skeletal muscle (Figure S9). High-fat
diet resulted in comparable increases in UCP1 mRNA in brown
fat, but not skeletal muscle, in both genotypes. In contrast,
UCP2 and UCP3 mRNA levels did not differ significantly by ge-
notype or dietary condition, consistent with previous reports
(Surwit et al., 1998).
Despite detection of ectopic orexin peptide in adrenal gland,
CAG/orexin mice and wild-type mice had similar total daily uri-
nary levels of epinephrine and norepinephrine and similar serum
corticosterone levels (Figure S10). In addition,CAG/orexin trans-
gene did not affect systolic blood pressure on either a low-fat or
high-fat diet (Figure S10).
OX2R Agonist Prevents Diet-Induced Obesity
Our genetic studies implicate the OX2R pathway as mediator of
the effects of orexin overexpression upon energy homeostasis.
To further test the hypothesis that central enhancement of
orexin-OX2R signaling confers resistance to diet-induced obe-
sity, an OX2R selective agonist [Ala11, D-Leu15] Orexin-B (Asahi
et al., 2003) was continuously infused in the lateral ventricles of
wild-type mice for 14 days. The administration of the OX2R se-
lective agonist suppressed weight gain on a high-fat diet without
altering weight homeostasis on a low-fat diet (Figure 5A). Impor-
tantly, the OX2R selective agonist had no obvious effect upon
OX2R-deficient mice on a high-fat diet (n = 4, weight gain
3.33 ± 0.61 g, p = 0.67), verifying the specificity of the agonist
in vivo. Following 14 days, the agonist-infused wild-type mice
gained significantly less fat mass than did the vehicle-injected
mice on a high-fat diet, and no effect was observed on a low-
fat diet (Figure 5B). When centrally infused mice fed a high-fat
diet were monitored in metabolic chambers, OX2R agonist infu-
sions resulted in consistently greater energy expenditures
(Figure 5C), but not RQs (Figure 5D) or locomotor activity (data
not shown), over vehicle-infused controls.
As sleep/wake disturbances could affect food intake and en-
ergy expenditure, we recorded EEG/EMG signals during central
OX2R agonist or vehicle infusions. Mice receiving OX2R agonist
exhibited total wake or sleep times during both light and dark
phases that closely resembled vehicle controls, irrespective of
dietary condition (Figure S11). As predicted from previous stud-
ies (Willie et al., 2003), OX2R agonism continued to promote con-
solidation of behavioral states, as demonstrated by increased
wake and NREM episode durations in mice maintained on
a low-fat diet. As this consolidation was not evident under
high-fat-fed conditions, sleep/wake change cannot be the pri-
mary cause in metabolic effects of enhanced orexin signaling
observed predominantly under high-fat conditions.
We observed an expected homeostatic reduction of food in-
take in mice maintained on a high-fat diet compared to a low-
fat diet (West et al., 1992), and administration of the agonist sig-
nificantly enhanced this effect by further suppressing food intake
selectively in mice fed a high-fat diet (Figure 5E). After 14 days of
OX2R agonist administration, we observed reduced hypotha-
lamic mRNA expression of orexigenic factors NPY and AGRP
on a high-fat diet compared to those on a low-fat diet (Figure 5F).
Indeed, the number of c-Fos-positive cells in ARH region was
significantly reduced in OX2R agonist-administered mice on
a high-fat diet (Figures 5G and 5H). The reduction of c-Fos-
positive cell number was particularly notable in the ventromedial
aspect of ARH (Figure 5G), in which orexigenic NPY/AGRP neu-
rons are located (Horvath, 2005), consistent with the observed
reduction in food intake and in NPY/AGRPmRNAs we observed
under this condition.
Leptin Mediates Antiobesity Effects of Orexin
Leptin negatively regulates body weight, suppresses food in-
take, and increases energy expenditure by inhibiting NPY/
AGRP neurons and activating POMC neurons of ARH. Diet-in-
duced obesity is associated with leptin resistance resulting
from signal transduction abnormalities in ARH (Myers et al.,
2008). OX2R is highly expressed in ARH, and the effects of circu-
lating leptin upon ARH resemble some effects of increased
orexin-OX2R signaling that we observed. We hypothesized,
therefore, that leptin signaling mediates some of the metabolic
effects of orexin. To examine the consequences of orexin signal-
ing enhancement on mice in the absence of leptin activity, we
crossed CAG/orexin-transgenic and leptin-deficient ob/ob lines.
Remarkably, the CAG/orexin transgene had no impact upon
weight gain or fat mass of leptin-deficient ob/ob mice (Figures
6A and 6B), suggesting that, indeed, the antiobesity effect of
CAG/orexin depends upon leptin activity. We then centrally ad-
ministered OX2R agonist to ob/ob mice and similarly found no
significant effect upon weight gain under low- or high-fat dietary
conditions (Figure 6C). We also observed no effect of OX2R ag-
onist compared to vehicle administration upon core body tem-
perature of ob/ob mice (data not shown).
We directly examined whether orexin overexpression alters
sensitivity to leptin. Leptin was continuously administered in
(D) The respiratory quotient of OX2R agonist-infused mice on a high-fat diet was similar to that of vehicle-infused mice.
(E) The average daily food intake of mice injected with the OX2R selective agonist or vehicle on different fat diets during 14 days.
(F) Hypothalamic gene expressions at the end of OX2R selective agonist administration are determined using q-PCR. Gene expressions are normalized by
GAPDH.
(G) Immunostaining for c-Fos in ARH region of mouse on a high-fat diet during central administration of OX2R agonist or vehicle; 3V, third ventricle.
(H) The number of c-Fos-positive cells in ARH region. The numbers of mice per group are 7–14mice for (A), (B), and (C); 6–7mice for (D), (G), and (H); and 5–6mice
for (E) and (F). Data are expressed as means ± SEM.
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the lateral ventricles ofCAG/orexin andwild-type littermate pairs.
Mice (3–4 months old) were maintained on a low-fat diet in order
to initially match as to body weight (WT 29.7 ± 3.6 ng/ml
and CAG/orexin 27.0 ± 3.1 ng/ml). Both wild-type mice and
CAG/orexin mice lost weight during the administration of leptin,
but CAG/orexinmice showed significantly enhanced weight loss
Figure 6. No Effect of Orexin Overexpression on the Weight Gain
of ob/ob Mouse
(A) The body weight growth of ob/ob;CAG/orexinmalemice was similar to that
of ob/ob male mice (p = 0.76).
(B) Fat mass of 28-week-old ob/ob male mice with or without CAG/orexin
transgene. There is no significant difference in fat mass for both male and
female. There were 13–20 mice per group.
(C) The bodyweight growth of OX2R agonist-infused ob/obmice was similar to
that of vehicle-injected ob/obmice maintained on a low-fat and a high-fat diet.
Data are expressed as means ± SEM.72 Cell Metabolism 9, 64–76, January 7, 2009 ª2009 Elsevier Inc.and anorexia compared to wild-type mice on a low-fat diet (Fig-
ures 7A and 7B), indicating that increased orexin signaling is as-
sociated with a more leptin-sensitive state.
Compared to control wild-type mice, 14 days of central leptin
administration resulted in basal hypothalamic expression levels
of NPY and AGRP and an expected induction of POMC mRNA
(Figure 7C). In contrast, under basal conditions, CAG/orexin
transgenic mice showed increased expression of NPY and
AGRP, but not POMC mRNA. While we detected no significant
changes in the expression of LEPR, SOCS3, or STAT3 gene
products, the overall profile of altered hypothalamic gene ex-
pression we detected is consistent with the physiological state
of anorexia and weight loss observed in mice undergoing leptin
administration.
DISCUSSION
When challenged with a high-fat diet, CAG/orexinmice maintain
elevated energy expenditure, decreased food intake, and resis-
tance to diet-induced obesity, hyperleptinemia, and hyperinsuli-
nemia, although these mice show normal adiposity and energy
homeostasis under a low-fat diet. Molecular genetic dissection
of the metabolic phenotype utilizing CAG/orexin; OX1R/ and
CAG/orexin; OX2R/ mice indicated that OX2R predominantly
mediates these antiadipogenic effects and improves insulin sen-
sitivity. Central infusion of an OX2R agonist confirms the role of
central orexin-OX2R signaling in protection from high-fat diet-
induced obesity. Furthermore, the antiadipogenic effects of ge-
netic or pharmacologic enhancement of orexin signaling require
leptin, and CAG/orexin mice exhibit increased sensitivity to ex-
ogenous leptin infusion.
Technical Considerations Regarding CAG/Orexin
Transgene
The CAG promoter is a universal, constitutively active promoter,
yet ectopic orexin production was restricted to a limited number
of tissues, likely due to the necessity of lineage-specific enzy-
matic machinery required for neuropeptide production. Like-
wise, immunohistochemical localization of orexin-A peptide
does not demonstrate homogenous presence of the antigen
throughout brain parenchyma, but restricted presence at spe-
cific brain regions. In CAG/orexin mice, the appearance and
number of strongly orexin-A-positive neurons in LHA (endoge-
nous orexin cells) and the density of orexin-A-positive fibers in
brain regions to which endogenous orexin neurons normally pro-
ject resemble wild-type mice (Figure S2). Additionally, we ob-
serve a diffuse background ectopic orexin-A immunoreactivity,
especially in the medial basal hypothalamus, including the
ARH (Figures S1 and S2). Ectopically expressed orexin confers
physiologic signaling, which is demonstrated by our previous re-
sult that the CAG/orexin transgene rescues the narcolepsy-
cataplexy phenotype (Mieda et al., 2004). Moreover, depen-
dency of the CAG/orexin phenotype upon the intact OX2R
gene demonstrates that the metabolic phenotype of CAG/orexin
mice is not an artifact, but the physiological effect of increased
orexin-OX2R signaling.
Although we cannot rule out a contribution of ectopic orexin
production in the thyroid, adrenal medulla, and pancreatic islets
to the phenotype of CAG/orexin mice, we found no indication of
Cell Metabolism
Antiobesity Effect of Orexin
Cell Metabolism
Antiobesity Effect of Orexinprimary peripheral endocrine disturbance in CAG/orexin mice.
CAG/orexin mice have normal levels of serum TSH, T3, T4, cor-
ticosteroid, and urinary catecholamines, and we observed im-
proved glucose metabolism consistent with increased insulin
sensitivity and reduced leptin levels that correspond in the ex-
pected manner to reduced adiposity. Furthermore, replication
of antiadipogenic effects with central OX2R agonist administra-
tion suggests that the metabolic effects of enhanced orexin sig-
naling originate centrally.
Orexin Signaling Promotes Negative Energy Balance
Energy balance is a function of caloric intake and energy expen-
diture, and our data indicate that both orexin overexpression and
OX2R agonist infusion increase energy expenditure and further
suppress consumption of a high-fat diet, providing the mecha-
nistic rationale for observed resistance to adiposity. While this
result seems at odds with the well-documented acute pharma-
cologic orexigenic activity of orexin (Sakurai et al., 1998; Willie
et al., 2001), chronic central administration of orexin-A does
not support increased food consumption or anabolism in rats
(Yamanaka et al., 1999). This suggests that the acute appetite-
promoting effects of orexin peptides may be temporary, or pro-
gressively overwhelmed by counterregulatory mechanisms that
oppose weight gain.
Low-fat-fed mice carrying the CAG/orexin transgene or
treated with OX2R agonist for 2 weeks demonstrated elevated
Figure 7. Increased Sensitivity of Orexin
Overexpression Mouse to Leptin
(A) The body weight changes during chronic ICV
injection of leptin (2 mg/day) for 14 days. CAG/
orexin mice on a low-fat diet show larger weight
loss compared with wild-type mice (p < 0.05).
(B) Daily food intake of CAG/orexin mice during
chronic injection of leptin is smaller than that of
wild-type mice.
(C) Hypothalamic gene expressions at the end of
leptin administration. There were 6–8 mice per
group. Data are expressed as means ± SEM
(*p < 0.05).
expression of the orexigenic genes NPY
and AGRP. These changes could repre-
sent a direct effect, as orexin acutely
stimulates neurons of the ARH when
microinjected (van den Top et al., 2004;
Yamanaka et al., 2000), and orexin-
stimulated food consumption depends
pharmacologically upon NPY signaling
(Yamanaka et al., 2000). An alternative
mechanism for upregulated NPY and
AGRP transcription could be a compen-
satory response to relative negative en-
ergy balance, since we noted significant
differences from controls only when
mice were maintained on calorie-poor
rather than calorie-dense chow.
Despite differences in orexigenic ef-
fects across different experimental para-
digms, consistent and unifying results from pharmacologic and
genetic studies indicate that orexin gain of function promotes en-
ergy expenditure while loss of function promotes energy conser-
vation. Just as the orexin system is believed to orchestrate dis-
parate circuits of the ascending arousal system to maintain
a consolidated state of arousal, it may also normally serve to
consolidate the activity in parallel reward and metabolic net-
works that control behavioral and homeostatic responses to
support energy expenditure. The exact peripheral (downstream)
mechanisms for the orexin-mediated increases of energy con-
sumption remain unclear. Although we did not detect significant
increase in urinary catecholamines or basal blood pressure, the
data do not exclude the possibility of a subtly increased sympa-
thetic tone in certain peripheral tissues. Indeed, we speculate
that the sympathetic pathways are one of likely downstream
mechanisms for the increased metabolic rate under enhanced
orexin signaling.
Interactions of Orexin and Leptin Signals
Antiadipogenic effects of orexin-OX2R signaling require the
presence of leptin, and orexin-overexpressing mice showed in-
creased sensitivity to catabolic-anorectic effects of exogenous
leptin. These findings suggest that leptin mediates the suppres-
sive effect of enhanced OX2R signaling on diet-induced obesity.
Leptin-responsive neurons are found in ARH, VMH, DMH, LHA,
and tuberomamillary nucleus of the hypothalamus (Elmquist,
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levels of OX2R, and exhibit ectopic orexin immunostaining in
CAG/orexin-transgenic mice. Among these, ARH is a particularly
critical nexus for body weight regulation that monitors peripheral
energy storages and enteral feeding status through integration of
circulating leptin and insulin, metabolites, and vagal relays.
Through outputs to other hypothalamic and brainstem sites,
ARH modulates the thresholds, triggering drives to eat and ex-
pend energy, and it influences insulin secretion and sensitivity
(Horvath, 2005; Coppari et al., 2005; Myers et al., 2008). More-
over, ARH harbors cellular abnormalities underlying acquired
leptin resistance (Kievit et al., 2006), and reduced leptin sensitiv-
ity in ARH has been causally linked with diet-induced obesity
(Enriori et al., 2007). While ARH neurons project to orexin neu-
rons of the LHA, ARH receives dense reciprocal orexin fiber
innervation and expresses mainly OX2R receptor (Cluderay
et al., 2002; Peyron et al., 1998; Marcus et al., 2001). Acute mi-
croinjections of orexin-A into ARH increase oxygen consumption
and body temperature under anesthesia (Wang et al., 2003).
The mechanism by which orexin and leptin signals interact re-
mains unclear. Neurons expressing both LEPR and OX2R may
have convergent intracellular second messenger signaling,
including extracellular factor-regulated kinase (ERK) and the
Janus kinase JAK2/STAT3 pathways (Myers et al., 2008; Zhu
et al., 2003). In ARH, leptin-responsive neurons such as those
expressing NPY/AGRP are directly excited by orexin while
POMC neurons are directly inhibited by orexin (Muroya et al.,
2004), but inhibitory GABAergic interneurons in ARH may also
be activated via postsynaptic OX2R (Burdakov et al., 2003), pre-
dicting complexity in up- or downregulation of these circuits. Fos
immunostaining reveals reduced neuronal activity in a population
of ARH neurons following 2 weeks of OX2R agonist administra-
tion on a high-fat diet, but the true molecular identity of these
cells and the direct versus indirect nature of this effect requires
investigation.
Orexin neurons could directly sense lipids through kinetics of
fatty acid metabolites to alter feeding behavior and energy
homeostasis. However, we observed CAG/orexin-transgenic
mice to be also resistant to aging-associated adiposity, even
when maintained on a low-fat diet, and we detected no signifi-
cant differences in circulating cholesterol or fatty acids among
genotypes or dietary conditions (data not shown). Therefore, ab-
normal kinetics of hypothalamic fatty acid metabolism alone is
unlikely to explain the obesity-resistant CAG/orexin phenotype.
Furthermore, endogenous orexin neurons are themselves un-
likely to play a crucial lipid-sensing role in energy homeostasis,
as CAG/orexin mice in which endogenous orexin neurons have
been selectively eliminated remain lean (J.T.W. and T.S., unpub-
lished data).
Potential Role of OX1R on Glucose Metabolism
The unifying scheme in the present study is that OX2R, but not
OX1R, is the primary receptor that mediates the beneficial
effects of orexin gain of function under a high-fat diet. The ob-
served improvements in glucose metabolism and insulin sensi-
tivity could largely be explained by the OX2R-mediated reduc-
tion of body adiposity. However, there is a notable exception:
we observed that OX1R deficiency alone, without orexin overex-
pression, can improve glycemia and insulin sensitivity on a high-74 Cell Metabolism 9, 64–76, January 7, 2009 ª2009 Elsevier Inc.fat diet (Figures 4A and 4B), despite the fact that OX1R/ and
wild-type mice are similarly obese under a high-fat diet (Figures
1C and 2C). This suggests that endogenous levels of orexin act-
ing onOX1Rmay, in part, mediate the deleterious effects of high-
fat diet on glucose metabolism. Indeed, OX1R is expressed in
the solitary tract nucleus and dorsal motor nucleus of the vagus
(Marcus et al., 2001), which participates in the regulation of he-
patic glucose production (Pocai et al., 2005). Although OX1R is
also detected in beta cells of pancreatic islets, a role for orexin,
if any, in the pancreatic islet is controversial (Heinonen et al.,
2008). At any rate, under orexin overexpression, the OX2R-me-
diated effects prevail, and the presence or absence of OX1R
does not affect (the improvement of) glycemia or insulinemia.
The specific role of OX1R on glucose regulation merits further in-
vestigation.
Therapeutic Implications
The robust innervation by the orexin system of the whole brain
and the multiple phenotypic aspects of orexin-deficient animals
such as cataplexy, attenuated morphine dependence, and di-
minished stress response has led to conceptualization of the
orexin system as a hypothalamic output pathway controlling
arousal, motivational behavior, and autonomic responses
(Chemelli et al., 1999; Sakurai, 2007). Our results demonstrate
that orexin signaling also has the capacity to primarily promote
energy expenditure via leptin sensitization. Augmentation of
OX2R signaling or its downstream targets beneficially alters hy-
pothalamic setpoints controlling metabolic rate, food intake, and
leptin and insulin sensitivity. Similar interventions in humans
might prevent or reverse the effects of consumption of calorie-
dense food that promote or maintain pathological adiposity
andmetabolic syndrome. From a therapeutic standpoint, it is im-
portant to note that orexin gain of function did not overtly alter the
basal blood pressure, or the thyroid, glucocorticoid, and cate-
choliamine statuses in our models.
While continuous orexin gain of function did not induce loco-
motor hyperactivity or perturb overall amounts of sleep and
wakefulness in CAG/orexin mice or OX2R agonist-infused
mice, further sleep/wake characterization of these models is
warranted. The metabolic syndrome is a disorder not only of
obesity and insulin insensitivity, but possibly also inactivity,
sleep/wake disturbances, and comorbid depression (Fabrica-
tore andWadden, 2006). Daytime administration of an OX2R ag-
onist to such individuals could havemultiple beneficial effects by
maintaining elevated metabolic rate while also promoting day-
time wakefulness and consolidating sleep/wake states. The
orexin system has emerged as a key target for therapeutic inter-
vention in disorders associated with hypothalamic dysfunction,
including not only narcolepsy and hypersomnia, but now also
the metabolic syndrome.
EXPERIMENTAL PROCEDURES
Animals
All mice were backcrossedmore than ten generations to the C57BL/6J strain. In
CAG/orexin-transgenicmice, theexpressionofprepro-orexin iscontrolledby the
chimericCAG promoter constructed from the chicken b-actin promoter and the
cytomegalovirus immediateearlygeneenhancer (Miedaetal., 2004).Eachgeno-
typic group was compared by pairing of littermates as follows: wild-type with
CAG/orexin, OX1R/ (Kisanuki et al., 2001) with OX1R/; CAG/orexin,
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CAG/orexin.Ob/ob (Zhang et al., 1994)micewere obtained from Jackson Lab-
oratory. Mice were provided food and water ad libitum, maintained on a 12 hr
light/dark cycle at all times, and housed at two or three mice per cage under
controlled temperature and humidity, unless otherwise specified. All proce-
dures were approved by the appropriate institutional animal care and use
committees and were carried out in strict accordance with NIH guidelines.
Body Weight Study
For diet-induced obesity, all mice were fed a low-fat diet (standard chow 8664
F6 Rodent Diet; Harlan Teklad) until 8 weeks of age. At 8 weeks of age, mice
were assigned randomly to either a low-fat or a high-fat diet (D12451; Re-
search Diets). A low-fat diet provided 4.1 kcal/g of energy (67% carbohydrate,
20% protein, and 13% fat). A high-fat diet provided 4.7 kcal/g of energy (35%
carbohydrate, 20% protein, and 45% fat). Body weight was measured weekly
until 30 weeks of age. At 28 weeks of age, mice were subjected to NMR (Min-
ispec NMR Analyzer; Bruker) to measure fat and lean mass per the manufac-
turer’s instructions. At 30 weeks of age, mice were euthanized to collect blood
and measure blood glucose. Serum was collected from centrifuged blood and
stored at80C until use. Ob/ob and ob/ob; CAG/orexinmice were fed a low-
fat diet until 30 weeks of age.
Blood Analysis
For analysis of serum, we used Mouse Leptin and Ultra Sensitive Rat Insulin
ELISA kits with Mouse Insulin Standard (Crystal Chem). Whole blood glucose
levels were measured using a standard clinical glucometer (Elite; Bayer). For
glucose tolerance tests, 21- to 25-week-old mice were fasted for 12 hr from
ZT16 and then injected with glucose (1.5 g/kg of body weight, i.p.) at ZT4.
Tail blood was collected at 0, 15, 30, 60, and 90 min after injection.
Metabolic Cage Study
Indirect calorimetry and locomotor data were simultaneously measured using
the Comprehensive Laboratory Animal Monitoring System (Columbus Instru-
ments). For genetic studies, 16- to 20-week-old animals were individually
housed in calorimeter chambers, and 3 days of data collection followed a 4
day acclimatization period. For pharmacologic studies, ICV cannulation sur-
gery was performed at 10–12 weeks of age, and high-fat feeding initiated in
an acclimatization chamber. After 4 days of acclimatization, each animal
was housed in a metabolic chamber for 4.5 days. We calculated metabolic
parameters based on the following equations:
RQ=CO2 production=oxygen consumption:
Raw Energy Expenditure ðREEÞ
= ð3:815+ 1:2323RQÞ3oxygen consumption:
Energy Expenditure with Effective Mass Correction
=REE=ðweight=mass unitÞeffective mass factor: Effective mass factor= 0:75:
Chronic ICV Injection
Three- to four-month-old male C57B/6J mice were single-housed 1 week be-
fore surgery and fed a low-fat diet. Mice were anesthetized with ketamine and
xylazine (100 mg/Kg and 10 mg/Kg, respectively, i.p.). A cannula (Brain Infu-
sion Kit III; Alzet) was implanted into the right lateral ventricle (0.3 mmposterior
from the bregma, 0.9 mm lateral from themidline, and 2.4mm from the surface
of skull) using standard sterile stereotactic techniques. An osmotic minipump
(model 2001; Alzet) was attached to the cannula and implanted in the subcu-
taneous space during the same surgical session. The OX2R selective agonist
([Ala11, D-Leu15] Orexin-B; American Peptide) (Asahi et al., 2003) or vehicle
was continuously injected in the lateral ventricle for 14 days (0.5 nmol/day).
The agonist was diluted with vehicle (Dulbecco’s PBS; Sigma) immediately be-
fore use. At the day of surgery, the implanted mice were randomly assigned to
a low-fat diet or a high-fat diet. Body weight and food intake were monitored
daily for 14 days, and fat mass was detected by NMR immediately after sur-
gery and again at day 14. Twelve-week-old ob/ob male mice were used for
chronic ICV infusion of OX2R agonist for 10 days as described above. Forleptin administration experiments, weight-matched 3- to 4-month-old
CAG/orexin and wild-type littermates were continuously injected with leptin
(2 mg/day; PreproTech), as described above, while maintained on a low-fat
diet. Body weight and food intake were monitored daily for 14 days.
Quantitative PCR
Hypothalamus was dissected coronally under microscope from the optic chi-
asm to the mamillary bodies. The thick coronal section was further trimmed
bilaterally at 1mm from themidline and dorsally at 1.5 mm from the ventral sur-
face. This dissected tissue included ARH, VMH, DMH, PVN, anterior hypotha-
lamic area, and a part of LHA. Total RNA was isolated using RNeasy Mini Kit
and used for cDNA synthesis by random hexamer and Omniscript Reverse
Transcriptase (QIAGEN). Real-time quantitative PCR reactions were per-
formed on cDNA with ABI Prism 7000 Sequence Detection System using
SYBRGreen PCRMaster Mix (Applied Biosystems) according to themanufac-
turer’s manual. GAPDH mRNA level was used for normalization.
Immunohistochemistry
After 2 weeks of continuous administration of OX2R agonist or PBS, mice on
a high-fat diet were harvested during early dark phase under a red light. The
immunohistochemistry for c-Fos was performed using free-floating method,
as described previously (Chemelli et al., 1999), utilizing anti-c-Fos polyclonal
antisera (Ab-5; Oncogene). Fos-positive cells in ARH region of two sections
per animal were counted by an observed blinded-to-treatment group.
Data Analysis
Body weight growths and glucose tolerance tests were examined using re-
peated-measure analysis of variance (ANOVA) followed by Tukey’s post hoc
test, except where otherwise specified.
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